Nexalin Technology (NXL) shares rose 15% in recent trading Tuesday after the company announced a planned clinical trial for its Gen-3 Halo headset to treat victims of traumatic brain injury.
The trial is in collaboration with the University of California, San Diego, the company said Tuesday in a statement.
The headset will be used in a virtual clinic model, and the trial will evaluate the effectiveness of the device on brain activity and symptom relief in veterans with mild traumatic brain injury, the company said.
Price: 1.71, Change: +0.23, Percent Change: +15.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。